This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignees: University of Michigan, Eli Lilly and Company. Active years: 1999-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ann Arbor, MI (US) (1999)
- Palo Alto, CA (US) (2001)
- Ann Arbor, CA (US) (2003)
Company Filing History:
Years Active: 1999-2025
Title: Erik J Hembre - Innovator in Pharmaceutical Research
Introduction
Erik J Hembre is an accomplished inventor based in Indianapolis, IN (US). He is currently associated with Eli Lilly and Company, where he contributes to innovative research in the pharmaceutical field. Although he has not yet been granted any patents, his work is focused on developing new treatments for various central nervous system disorders.
Latest Patent Applications
Erik J Hembre's notable patent application is titled "Phenyl-3,4-dihydroisoquinolin-2(1H)-yl-ethan-1-one derivatives as dopamine D1 receptor positive allosteric modulators." This invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), along with pharmaceutical compositions thereof. The application further outlines methods for using a compound of formula I to treat symptoms of dopaminergic CNS disorders, including Parkinson's disease, Schizophrenia, ADHD, and Alzheimer's disease.
Conclusion
Erik J Hembre is a promising inventor whose research has the potential to significantly impact the treatment of CNS disorders. His innovative approach and dedication to pharmaceutical research highlight the importance of continued exploration in this vital field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile